Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,526 | 0,574 | 21:47 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
18:06 | Oncodesign Precision Medicine: OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson's Research | 155 | Business Wire | OPM will contribute its unique expertise in kinase inhibitor development and its Nanocyclix®-derived compound OPM-201 to the LITE program OPM will leverage the LITE consortium to accelerate... ► Artikel lesen | |
31.07. | Oncodesign Precision Medicine: OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position | 451 | Business Wire | The REVERT Phase 1b/2a clinical trial evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 has been submitted to the Swiss regulatory (Swissmedic) and ethics (Swiss ethics)... ► Artikel lesen | |
11.07. | Oncodesign Precision Medicine - Precision therapies for resistant diseases | 377 | Edison Investment Research | Oncodesign Precision Medicine (OPM) is a clinical-stage biopharmaceutical company listed on Euronext Growth Paris. OPM is developing precision medicine therapies targeting treatment-resistant and metastatic... ► Artikel lesen | |
17.04. | Oncodesign Precision Medicine Announces Equity Financing of up to 5 Million Euros | 329 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
03.04. | Oncodesign Precision Medicine: OPM Announces Its 2024 Annual Results and Clinical Developments | 355 | Business Wire | OPM-101: preclinical work establishing POC in immuno-oncology, end of phase 1 healthy volunteers and preparation for phase 1b/2a Reintegration of OPM-201 into OPM's portfolio of proprietary... ► Artikel lesen | |
24.03. | Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1 | 496 | Business Wire | OPM-101 will be evaluated in a Phase 1b/2a clinical trial, in combination with pembrolizumab, a monoclonal antibody directed against the PD-1 protein, in patients with advanced melanoma resistant... ► Artikel lesen | |
04.03. | Oncodesign Precision Medicine: Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors | 383 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
20.12.24 | Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers | 427 | Business Wire | Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers
Regulatory News:
Oncodesign Precision... ► Artikel lesen | |
22.10.24 | Oncodesign Precision Medicine: OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a | 459 | Business Wire | Finalization of the study report on the double-blind, placebo-controlled Phase 1 trial of OPM-101 in 104 healthy volunteers (HV) who received OPM-101 24-hour ECG analysis reveals no toxic... ► Artikel lesen | |
15.10.24 | Oncodesign Precision Medicine: OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference | 364 | Business Wire | Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 37,645 | -2,03 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
EVOTEC | 6,038 | -3,05 % | Adidas schluckt Puma? Evotec mit Insiderkauf! 50 % Kurspotenzial mit KI-Aktie NetraMark! | Adidas und Puma im Fusionsfieber? Ein US-Investor bringt die spektakuläre Idee ins Spiel. Ist es ein Druckmittel gegenüber dem Puma-Management oder tatsächlich eine Option? Was sagen Analysten? Währenddessen... ► Artikel lesen | |
SCISPARC | 6,130 | +60,05 % | SciSparc stock soars after launching quantum computing initiative | ||
PEPGEN | 5,590 | +110,94 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
IMMUNEERING | 7,615 | -17,14 % | Mizuho bestätigt Outperform-Rating für Immuneering nach positiven Studiendaten | ||
BIONTECH | 84,40 | -0,76 % | PAUKENSCHLÄGE bei Megatrend-Aktien: Rheinmetall, BioNTech, First Hydrogen | Rheinmetall gibt Vollgas: zu Land, zu Wasser, in der Luft und im Weltraum. Jüngster Paukenschlag ist die angekündigte Übernahme der Marinesparte von Lürssen. Ist das der Rückenwind für die Aktie, um... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,645 | -4,82 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
MINERALYS THERAPEUTICS | 38,750 | -0,49 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
MBX BIOSCIENCES | 17,430 | -14,22 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen | |
EVAXION | 4,490 | +36,06 % | Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co. | KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license... ► Artikel lesen | |
TOURMALINE BIO | 47,730 | -0,03 % | Tourmaline Bio To Be Acquired By Novartis; Was TRML Stock In Your Investment Portfolio? | BASEL (dpa-AFX) - Tourmaline Bio Inc. (TRML), a late-stage clinical biotechnology company developing medicines for life-altering inflammatory and immune diseases, is all set to be acquired by... ► Artikel lesen | |
UNIQURE | 44,370 | +9,64 % | XFRA UQ1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILUNIQURE N.V. EO... ► Artikel lesen | |
OCUGEN | 1,310 | -5,96 % | Forecasting The Future: 4 Analyst Projections For Ocugen | ||
VERA THERAPEUTICS | 27,440 | +5,70 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,310 | -0,98 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen |